The Service Line

8 billion dollars: the price tag on the largest deal in radiopharmaceutical industry history, and it is a bet that targeted radiation, not chemotherapy, is where cancer treatment margin moves next. Curium, a global manufacturer of diagnostic and therapeutic radiopharmaceuticals selling into more than 70 countries, announced a definitive agreement August 3, 2026 to acquire Lantheus Holdings, Inc. for 102.50 dollars per share in cash at closing, plus a contingent value right (CVR) worth up to 12.00 dollars per share tied to sales milestones through 2030, for total consideration up to 114.50 dollars per share and roughly 8 billion dollars overall; the deal is expected to close in the first half of 2027, subject to shareholder approval and regulatory clearance. Lantheus’s oncology franchise centers on PYLARIFY, the prostate-specific membrane antigen (PSMA) PET imaging agent for prostate cancer that generated 240.9 million dollars in the first quarter of 2026 alone even as competitive pricing pressure trimmed sales 6.5 percent year over year. For oncology and imaging practices, the deal signals that the isotope production, distribution and imaging-agent manufacturing layer feeding every PSMA scan and radioligand therapy infusion is consolidating into fewer, larger hands even as clinical demand grows; active global radiopharmaceutical trials grew roughly tenfold since 2018, from a handful to more than 80 by August 2025, according to trial-site-readiness tracking compiled for the Society for Clinical Research Sites. Confidence: High on the deal’s terms, from Curium’s own release; Medium on how the combined company’s manufacturing scale affects isotope and tracer supply reliability for community oncology and imaging practices, since that operational detail has not yet been addressed by either company. Sources: Curium Announces Definitive Agreement to Merge with Lantheus, Curium Pharma, Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update, Lantheus Holdings, Inc..

Reimbursement

CMS wants oncology and infusion sites reporting quarterly to a new federal claims database starting January 1, 2027, the price of keeping the 340B drug discount. The Centers for Medicare and Medicaid Services (CMS) released its Calendar Year (CY) 2027 Medicare Physician Fee Schedule (MPFS) proposed rule (CMS-1848-P) July 14, 2026, and inside a rule best known for cutting the physician conversion factor sits a new mandate: every 340B Drug Pricing Program covered entity, including hospital-affiliated oncology and infusion sites, must submit quarterly Part D claims data, including date of service, prescription reference number, National Drug Code and 340B identifying information, to a CMS repository starting January 1, 2027. The same rule proposes converting the G2211 visit-complexity add-on, the code oncologists and other cognitively complex specialists use heavily alongside 99214 and 99215 evaluation and management (E/M) visits, from a flat add-on into a percentage modifier, cutting the qualifying alternative payment model (APM) conversion factor from 33.5675 dollars to 33.1693 dollars (a 1.19 percent reduction), and raising the Medicare Shared Savings Program (MSSP) BASIC Track Level E shared savings rate from 50 percent to 60 percent. Comments close September 14, 2026. For oncology practices weighing 340B contract-pharmacy arrangements or accountable care organization (ACO) participation, both provisions are worth modeling now, not after the rule finalizes; see this week’s Operator Metric for the G2211 detail. Confidence: High on the rule’s proposed terms, from CMS’s own materials; Low on whether the 340B reporting mandate and G2211 restructuring survive comment unchanged. Sources: Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule, CMS, CMS Issues CY 2027 Medicare Physician Fee Schedule Proposed Rule, Holland and Knight.

Enforcement

No new national oncology-specific fraud enforcement action broke in the two weeks since our last coverage. HHS Office of Inspector General’s (OIG) own “what’s new” tracker and the Department of Justice’s most recent national health care fraud takedown (June 23, 2026, 455 defendants, 6.5 billion dollars alleged) named zero oncology, chemotherapy or infusion defendants this window. We will flag the next one the day it lands.

Who’s Buying

Today’s lede story, Curium’s acquisition of Lantheus, is this week’s biggest oncology-adjacent deal; see above. On the delivery side of the same radiopharmaceutical build-out, American Oncology Network (AON), the community oncology network headquartered in Fort Myers, Florida, announced July 23, 2026 that it now operates nine active radioligand therapy centers nationwide, up from a single site in 2023, with five more in development, alongside two new physician leaders: Robert J. McDonald, MD, as radiology medical director and Jason Berilgen, MD, as radiation oncology medical director. Together, the two stories show radiopharmaceutical capacity concentrating at both ends of the supply chain, manufacturing and distribution consolidating into fewer companies while delivery capacity concentrates into networks large enough to fund the physician training, facility build-out and regulatory work an independent single-site practice cannot easily absorb alone. Confidence: High on both companies’ own announcements; Medium on how directly the two trends are causally linked, since AON and Curium-Lantheus are unrelated corporate actors responding to the same market signal rather than parties to one transaction. Source: American Oncology Network Expands Radiology and Imaging Program with New Physician Leaders and Advances Radiopharmaceutical Therapies, GlobeNewswire.

Clinical Policy

GSK’s first lung cancer drug approval arrived one week after the company finished buying the small biotech that invented it. The Food and Drug Administration (FDA) approved zidesamtinib (Jideytro, GSK plc) July 22, 2026 for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who progressed on a prior ROS1 tyrosine kinase inhibitor (TKI); GSK’s acquisition of the drug’s originator, Nuvalent, Inc., closed July 15, 2026, one week before approval. In the pivotal ARROS-1 trial, zidesamtinib produced a 44 percent overall response rate across 117 previously treated patients, with 82 percent of responses still ongoing at six months and 69 percent at twelve months, including activity against brain metastases and ROS1 resistance mutations that limit older-generation inhibitors. The drug is an oral, 100 milligram once-daily tablet, meaning it bills through Medicare Part D rather than the buy-and-bill Part B system that governs infused oncolytics; practices with a ROS1-positive lung cancer population should update treatment pathways and prior-authorization workflows now that a second-line option exists beyond the current ROS1 TKI class. Confidence: High on the approval and trial results, drawn from GSK’s own release. Source: Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer, GSK plc.

The Operator Metric

32 percent: the enhanced payment bump CMS is proposing for complex E/M visits billed by oncologists in MSSP Advanced or LEAD-track ACOs, against 16 percent for everyone else. Buried in the same CY2027 Medicare Physician Fee Schedule proposed rule covered above, the restructured G2211 add-on effectively doubles the complexity-visit payment for oncology and other cognitively demanding practices willing to take on ACO-level accountability, a direct financial nudge toward the value-based-care participation question every community oncology practice already weighs against Enhancing Oncology Model (EOM) downside risk. A practice with a heavy 99214 and 99215 visit mix should model both tracks side by side this fall, since the gap between 16 percent and 32 percent compounds across thousands of annual E/M visits and could tip the ACO participation math independent of EOM’s own shared-savings terms. Comments on the proposal close September 14, 2026. Confidence: High on the proposed rate structure, from CMS’s own rule; Low on whether the enhanced tier survives finalization unchanged, since G2211 policy has shifted with nearly every rulemaking cycle since the code’s 2021 creation. Source: Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule, CMS.